With modern therapies for heart failure (HF) with reduced ejection fraction (HFrEF), some patients can improve their cardiac function during treatment.
The latest guidance in addressing proper monitoring and reversal of neuromuscular blockade drugs during general anesthesia – a major advance in patient safety and satisfaction – was published today in Anesthesiology, the American Society of Anesthesiologist’s (ASA) peer-reviewed medical journal.
Abhinav Jha, at the McKelvey School of Engineering, wants to use novel imaging to better understand how people absorb radiation therapy. His team won a four-year $2.2 million National Institutes of Health (NIH) grant for the study, which aims to guide treatment decisions.
A serious condition that can cause the kidneys to suddenly stop working could be treated with existing medicines, a new study shows.
As human lifespans increase, so does general memory impairment – calling for the need to expand research for dementia treatment. The key to this expansion is the center focus of the SLAS Discovery featured article, “A neuronal cell-based reporter system for monitoring the activity of HDAC2” by Unemura, et al.
An analysis of combined pharmacotherapy for reducing drinking and smoking validated findings that measuring reductions in the amount of drinking, not just abstinence, was an effective outcome for alcohol medication trials.
Pesquisadores da Mayo Clinic dizem que o anticorpo monoclonal bebtelovimabe (já autorizado pela Food and Drug Administration para uso emergencial na variante ômicron da COVID-19) é uma opção confiável para tratar a BA.2 e outras subvariantes da COVID-19. As descobertas do estudo retrospectivo realizado vários locais, envolvendo 3.607 pacientes de alto risco foram publicadas na revista médica Journal of Infectious Diseases.
Los investigadores de Mayo Clinic informan que el anticuerpo monoclonal bebtelovimab, ya autorizado por la Administración de Alimentos y Medicamentos de Estados Unidos para usar en emergencias de la variante ómicron de la COVID-19, es una alternativa confiable para tratar a la BA.2 y otras subvariantes de la COVID-19. Los resultados del estudio retrospectivo que se realizó en varios sitios con 3607 pacientes de alto riesgo se publicaron en Journal of Infectious Diseases (Revista de Enfermedades Infecciosas).
مدينة روتشستر، ولاية مينيسوتا - يقول باحثو مايو كلينك إن الجسم المضاد أحادي النسيلة ببتيلوفيماب، المُرخص بالفعل من قبل إدارة الغذاء والدواء الأمريكية للاستخدام في حالات الطوارئ الخاصة بمتحور أوميكرون من فيروس كورونا المستجد (كوفيد-19)، هو خيار موثوق لعلاج سلالة BA.2 والمتحورات الفرعية الأخرى لفيروس كورونا المستجد (كوفيد-19). ونتائج دراستهم الاسترجاعية متعددة المواقع والتي شملت 3,607 مريضًا معرضين لمخاطر عالية، منشورة في مجلة الأمراض المعدية.
A retrospective cohort study of more than 44,000 nonhospitalized persons diagnosed with COVID-19 found that nirmatrelvir plus ritonavir reduced the overall risk of hospitalization and death. The study is published in Annals of Internal Medicine.
Researchers from Tel Aviv University developed a new technology that will allow controlled encapsulation and release of molecules by exposure to UV light.
A first-of-its-kind drug known as modakafusp alfa has shown early potential in combating multiple myeloma, a form of bone marrow cancer, in a study presented by researchers from the University of Pennsylvania’s Abramson Cancer Center at the 2022 American Society of Hematology (ASH) Annual Meeting (Abstract 565).
Researchers have used gold extracted from electronic waste as catalysts for reactions that could be applied to making medicines.
Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped
The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been devastating the entire world.
"This is a very striking and significant result that essentially separates LIGHT from any of the other inflammatory cytokines that have been implicated in the process in severe asthmatics."
Johns Hopkins Medicine researchers continue their exploration into psychedelics and how these drugs may produce a wide range of profound changes in perception, cognition and mood.
The December 2022 issue features 10 articles on the latest research in toxicology.
For decades, doctors have treated kids with attention-deficit/hyperactivity disorder (ADHD) with methylphenidate, a stimulant drug sold as Ritalin and Concerta, making it one of the most widely prescribed medications aimed at the central nervous system.
The University of California, San Francisco, and Johns Hopkins University today expanded the UCSF-JHU Opioid Industry Documents Archive, adding one million pages of records from Insys Therapeutics—which manufactured and marketed the fentanyl spray Subsys.
Many pathogenic viruses, including herpesviruses, SARS -Cov-2, cytomegalovirus, papillomavirus, virus Nipah and others, use the similar mechanism to join the target cells, which consists in their attachment to heparan sulfate proteoglycan of the cell membrane.
According to a paper published in Chemical Engineering Journal recently, a team from the High Magnetic Field Laboratory (HMFL), Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences, successfully designed a safe and efficient nanotorpedo for the delivery of chemotherapeutic drugs.
People who take cholesterol-lowering drugs called statins may have a lower risk of having a type of stroke called an intracerebral hemorrhage, according to a new study published in the December 7, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology. An intracerebral hemorrhage is caused by bleeding in the brain.
Scientists at Dana-Farber Cancer Institute have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant. The drug is designed in such a way that natural selection to maintain infectiousness of the virus should also maintain the drug’s activity against future variants.
A largescale new study offers a new approach to treating in type 2 diabetes - that puts patients in charge of their own medication.
Christine Strand Bachmann has led a study that includes all Norwegian children born between 1989 and 1998, a total of 488 000 people.
Physician-scientists from Cedars-Sinai Cancer are available for comment on research being presented throughout the San Antonio Breast Cancer Symposium, taking place Dec. 6-10.
A newly discovered technique, reported in the journal Nanoscale, offers a low-cost way to enhance the effectiveness of existing drugs.
While many new medications designed to treat neurologic diseases have hit the market, utilization by patients remains low due to high costs and similar effectiveness to existing drugs, a new study funded by the American Academy of Neurology finds.
Teens with Type 1 diabetes (T1D) who took bromocriptine, a medication used to treat Parkinson’s disease and Type 2 diabetes, had lower blood pressure and less stiff arteries after one month of treatment compared to those who did not take the medicine, according to a small study published today in Hypertension, an American Heart Association journal.
A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers from Penn Medicine’s Abramson Cancer Center showed.
Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced the risk for hospitalization for any cause in patients with chronic kidney disease (CKD) with and without type 2 diabetes.
By simulating molecular dynamics, scientists from St. Jude Children’s Research Hospital revealed how the selectivity or promiscuity of GPCR coupling relies on the location and duration of intermolecular interactions.
Henry Ford Health Orthopedic researchers looked at steroids as part of a multi-modal pain control regimen and an alternative to using opioids after outpatient knee replacement. The study won the 2022 American Association of Hip and Knee Surgeons Clinical Research Award.
A new trial will test whether a medication that targets gut bacteria can also improve irritability in teenagers with autism spectrum disorder.
Researchers at The Tisch Cancer Institute uncovered inflammatory markers that may predict which COVID-19 patients are more likely to respond to therapies like the anti-cancer drug pacritinib, according to phase 2 trial results published in JAMA Network Open in December.
Scientists have created a much faster way to make certain complex molecules, which are widely used by pharmaceuticals for antibiotics and anti-fungal medicines.
The life expectancy of women is significantly higher than that of men.
Researchers find that the anesthetic and fast-acting antidepressant switches natural patterns of neuronal activity in the cortex of mice
A Phase 2 clinical trial has started of DS-1211 in individuals with Pseudoxanthoma Elasticum (PXE), a rare multisystem genetic disease that causes calcium deposits in soft tissue resulting in considerable morbidity. DS-1211 is a potential first-in-class small molecule developed through a research collaboration between Daiichi Sankyo and Sanford Burnham Prebys.
While it has long been recognized that drugs that block the cancer-promoting activity of estrogen reduce risk of developing new breast cancers, a new computer modeling study led by researchers at Georgetown Lombardi Comprehensive Cancer Center and colleagues showed that these treatments could also reduce the risk of dying from the disease in women who are at high risk.
Experts reviewing the use of a commonly prescribed family of drugs, known as fluoroquinolones, say safety warnings differ internationally
Researchers found that using buprenorphine to treat opioid-use disorder during pregnancy may result in better outcomes for the baby than methadone.
When the U.S. Food and Drug Administration gave controversial accelerated approval to the first Alzheimer’s drug in nearly 20 years, it had a surprising impact on attitudes about research into the disease.
A number of new neurologic medications for diseases like multiple sclerosis (MS), Parkinson’s disease and migraine have received U.S. Food and Drug Administration (FDA) approval over the past decade. However, with most having higher out-of-pocket costs and benefits similar to existing, less expensive drugs, only a small percentage of people with neurologic conditions are being treated with these new drugs, according to a study funded by the American Academy of Neurology and published in the November 30, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology.
A pilot, “look-back” study of information about 106 patients with “wet” age-related macular degeneration (AMD) treated at the Wilmer Eye Institute at Johns Hopkins Medicine has revealed that nearly half of patients treated with aflibercept could safely stop eye injection therapy after one year without further vision loss.
Reported in Nature, UNC School of Medicine scientists used cryogenic electron microscopy to determine the detailed, high-resolution structures of four designer receptors bound to three drug-like but inert compounds, a major advance in chemogenetics research.
Cedars-Sinai Pharmacy experts will present their latest advances in research and care in person at the midyear clinical meeting of the American Society of Health-System Pharmacists (ASHP) in Las Vegas Dec. 4-8, sharing innovations to improve medication safety, availability and effectiveness for hospital patients.
With a new $3 million-plus grant from the National Institutes of Health (NIH), Case Western Reserve University researchers are examining the next level of treatment for Candida auris (C.auris), a multidrug-resistant yeast that causes serious infection and, in some cases, death.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
